Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 17/20 | 0.45 |
| ▸ | MAPK11 | Q15759 | 9/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 8/20 | 0.45 |
| ▸ | MAPK12 | P53778 | 8/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2025620 | 0.85 | MAPK14 (0.48) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2082236 | 0.84 | MAPK14 (0.42) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2025289 | 0.82 | HPGD (0.43) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2081248 | 0.82 | CYP1A2 (0.40) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| Hydrochloric Acid SCHEMBL2025286 | 0.82 | HPGD (0.42) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2084331 | 0.82 | MAPK14 (0.40) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2082586 | 0.81 | RAB9A (0.42) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2084328 | 0.78 | MAPK14 (0.42) | MAPK14MAPK11MAPK13MAPK12DDR2 | |
| SCHEMBL2084854 | 0.77 | CDC25B (0.43) | MAPK14MAPK9HPGDKMT2A | |
| SCHEMBL14190032 | 0.77 | CYP1A2 (0.36) | MAPK14MAPK11MAPK13MAPK12DDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2942349-A1 | ENZYME MODULATORS AND TREATMENTS | Deciphera Pharmaceuticals, LLC (US) | 2015-11-11 | — | — | EP | disclosed |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | disclosed |
| US-20070078121-A1 | Enzyme modulators and treatments | DECIPHERA PHARMACEUTICALS, LLC | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078121-A1 | Enzyme modulators and treatments | ABL1, ABL2, LCK | MAPK14 128/4885MAPK11 242/4885MAPK13 162/4885 |
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAPK14 100/4885MAPK11 189/4885MAPK13 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.